The ability of antisera raised against a candidate Japanese encephalitis virus (JEV) vaccine, ChimeriVax™-JE, and the currently licensed vaccine, JE-VAX®, to protect against strains of JEV representing the four major genotypes was assessed. Neutralization assays and passive protection studies in mice showed that greatest protection was provided against strains of genotypes II and III, although some protection was also afforded against genotypes I and IV strains. ChimeriVax™-JE stimulated protection that was comparable or superior to the JE-VAX® control.
- Japanese encephalitis virus
ASJC Scopus subject areas
- Molecular Medicine
- Immunology and Microbiology(all)
- Public Health, Environmental and Occupational Health
- Infectious Diseases